#China #Hong Kong #Ascletis #ASC47 #ASC31

Ascletis Reveals Groundbreaking Findings on Weight Loss Drugs

Ascletis Pharma Inc. has unveiled remarkable results from its preclinical studies involving ASC47, a groundbreaking muscle-preserving drug designed for weight management. This innovative treatment, combined with ASC31—an advanced dual peptide agonist targeting both the GLP-1 receptor (GLP-1R) and GIP receptor (GIPR)—has exhibited promising efficacy in an animal model of obesity.

In a recent study using diet-induced obese (DIO) mice, this combination achieved a staggering 44.8% reduction in body weight over just 14 days. This impressive outcome significantly outperformed the combination of ASC47 and tirzepatide, which resulted in a lesser weight loss of 38.1% during the same period. According to Ascletis, these findings not only validate their innovative approach but also highlight the potential for ASC47 and ASC31 to redefine obesity treatment paradigms.

Ascletis's approach with ASC31, a novel peptide agonist, leverages its in-house advancements. This drug candidate has shown a favorable pharmacokinetic profile in non-human primates, alongside positive in vitro activities and a solid performance in vivo. The combined strengths of ASC47's adipose-targeting capabilities and ASC31's dual action mechanism position this treatment as a potential best-in-class product against obesity.

The design of this preclinical trial aimed to directly compare the efficacy of ASC47 when paired with ASC31 versus its pairing with tirzepatide. The remarkable findings—showcasing a 17.6% higher effectiveness with the new dual agonist—underscore the innovative efforts underway at Ascletis. Dr. Jinzi Jason Wu, the founder and CEO of Ascletis, expressed optimism about these results, emphasizing their potential to distinguish this treatment from existing options available in the market.

Ascletis is dedicated to developing cutting-edge therapeutics for metabolic disorders, employing advanced methodologies such as the Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and the Ultra-Long-Acting Platform (ULAP). Their commitment to research and development has fostered an impressive array of drug candidates, including their leading program, ASC30, which is focused on GLP-1R agonism for effective weight management.

The overarching goal of Ascletis is to address the rising global epidemic of obesity through innovative drug therapies. The company is poised for significant advancements in the near future as they continue to expand their pipeline of small molecules and peptides targeting this critical health issue. As clinical trials progress, stakeholders and the medical community are invited to stay informed of further developments from Ascletis.

In summary, Ascletis Pharma Inc. is at the forefront of pioneering strategies in the fight against obesity. As they continue to navigate the complexities of drug development, the success of ASC47 and ASC31 serves as a beacon of hope for millions affected by weight-related challenges. The company remains committed to enhancing the quality of life through groundbreaking therapeutic options, making significant strides toward a healthier future.